No Data
The 5 consecutive limit-up days for Mebon Co., Ltd. (605033.SH): The "one certificate, one product" policy has little impact on the company.
On January 8, Gelonghui reported that Meibang Co., Ltd. (605033.SH) announced that the "one certificate, one product" policy has a minor impact on the company. The company has been complying with national policies for registration, and its production and operation are currently normal. There have been no significant changes in the main Business, and the external environment has not changed significantly. Given the recent volatility in the company's Stocks trading prices, which have closed at the limit-up price for five consecutive trading days, there is a high risk of speculation. The company's main Business focuses on the research, production, and sales of pesticide products, as well as the promotion and service of Agriculture technology, and currently, its production and operation are normal with no significant changes in the main Business, and the external environment has not undergone significant changes.
What Shaanxi Meibang Pharmaceutical Group Co., Ltd.'s (SHSE:605033) 28% Share Price Gain Is Not Telling You
Three consecutive boards & "Heaven and Earth" giant shock. Meibang Co., Ltd. (605033.SH): Trade volume has increased significantly, Operation is normal and there are no major changes in the main business.
Meibang Co., Ltd. (605033.SH) announced that the company's Stocks will be continuously suspended on January 2 and January 3, 2025...
In 10 minutes, the stock went from a limit decrease to a limit increase, what a stunning turnaround for Meibang Co.! Who is buying and who is selling?
The battle between bulls and bears is intense.
Meibang Co., Ltd. (605033.SH) announced a dividend of 0.045 yuan per share for the first three quarters, with the equity registration date on December 18.
Meibang Co., Ltd. (605033.SH) announced that the company will implement equity distribution for the first three quarters of 2024, with a dividend per share ...
Shaanxi Meibang Pharmaceutical Group to Terminate Bond Issue
No Data